Taken together, the in vivo data suggests that ALDH1A3’s effects on tumor growth are reflected in the changes it induces in the CD24−CD44+ cell population and the overall tumor-initiating cell frequency, which are also susceptible to the glycolysis inhibitor 2DG. This evidence concerns the gene ALDH1A3 and neoplasm.